R
Ran Wu
Researcher at Yale University
Publications - 60
Citations - 2585
Ran Wu is an academic researcher from Yale University. The author has contributed to research in topics: Smoking cessation & Abstinence. The author has an hindex of 27, co-authored 57 publications receiving 2311 citations.
Papers
More filters
Journal ArticleDOI
Gender-Related Differences in the Characteristics of Problem Gamblers Using a Gambling Helpline
Marc N. Potenza,Marvin A. Steinberg,Susan D. McLaughlin,Ran Wu,Bruce J. Rounsaville,Stephanie S. O'Malley +5 more
TL;DR: Individuals with gambling disorders have gender-related differences in underlying motivations to gamble and in problems generated by excessive gambling.
Journal ArticleDOI
Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial.
Benjamin A. Toll,Stephanie S. O'Malley,Nicole A. Katulak,Ran Wu,Joel A. Dubin,Amy E. Latimer,Boris Meandzija,Tony P. George,Peter Jatlow,Judith L. Cooney,Peter Salovey +10 more
TL;DR: It is suggested that gain-framed messages may be more persuasive than loss- Framed messages in promoting early success in smoking cessation for participants who are engaged in treatment.
Journal ArticleDOI
Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: A nested sequence of 3 randomized trials
Stephanie S. O'Malley,Bruce J. Rounsaville,Conor K. Farren,Kee Namkoong,Ran Wu,Jane E. Robinson,Patrick G. O'Connor +6 more
TL;DR: Maintenance of improvement was enhanced by continued naltrexone treatment in the PCM but not in the CBT arm, and comparable results during the initial 10 weeks of treatment when combined with PCM or CBT.
Journal ArticleDOI
A preliminary investigation of varenicline for heavy drinking smokers.
Lisa M. Fucito,Benjamin A. Toll,Benjamin A. Toll,Ran Wu,Denise M. Romano,Ece Tek,Stephanie S. O'Malley,Stephanie S. O'Malley +7 more
TL;DR: Findings from this preliminary study suggest that varenicline may be a promising strategy for concurrently reducing heavy drinking and promoting smoking changes in heavy drinkers.
Journal ArticleDOI
A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.
Stephanie S. O'Malley,Judith L. Cooney,Suchitra Krishnan-Sarin,Joel A. Dubin,Sherry A. McKee,Ned L. Cooney,Amy Blakeslee,Boris Meandzija,Denise Romano-Dahlgard,Ran Wu,Robert W. Makuch,Peter Jatlow +11 more
TL;DR: The significant weight reduction with low-dose naltrexone therapy suggests that it may be useful as a second-line treatment for weight-concerned smokers.